Taylor & Francis Group
Browse
yner_a_1576375_sm2486.pdf (1.26 MB)

ECAS progression score: a web-based model to predict progression of extracranial carotid artery stenosis

Download (1.26 MB)
journal contribution
posted on 2019-02-13, 17:47 authored by Ruijun Ji, Kai Yu, Guoyang Li, Xinyu Liu, Yinglin Yan, Suying Gao, Hongna Yang, Shangmin Qin, Fang Li, Guangbo Zhang, Bo Yang, Yan He, Yongna Zhao, Enjing Li, Lihua Xu, Na Zhang, Dongna Fan, Dongliang Liu

Background and purpose: To develop and validate a risk model (Extracranial Carotid Artery Stenosis progression score, ECAS-PS) and to predict risk of ECAS progression.

Methods: The ECAS-PS was developed based on the Renqiu Stroke Screening Study (RSSS), in which eligible participants were randomly divided into derivation (60%) and validation (40%) cohorts. ECAS at baseline and follow-up was diagosed by carotid duplex ultrasound according to the published criteria. ECAS progression was defined as an increase in ECAS to≥50% for those with a baseline of <50% or as an increase to a higher category of stenosis if the baseline stenosis was ≥50%. Independent predictors of ECAS progression were obtained using multivariable logistic regression. The area under the receiver operating characteristic curve (AUROC) and the Hosmer–Lemeshow test were used to assess model discrimination and calibration.

Results: A total of 4111 participants were included and the mean age was 64.3. A total number of 29 (0.7%), 24 (0.6%) and 48 (1.2%) patients progressed during 2-year follow-up for left, right and bilateral (either left or right) carotid artery, respectively. The ECAS-PS was developed from a set of predictors of ECAS progression. The ECAS-PS demonstrated good discrimination in both the derivation and validation cohorts (AUROC range: 0.824–0.917). The Hosmer–Lemeshow tests of ECAS progression score were not significant in the derivation and validation cohorts (all P > 0.05).

Conclusion: The ECAS progression score is a valid model for predicting the risk of ECAS progression. Further validation of the ECAS-PS in different populations and larger samples is warranted.

Funding

The Renqiu Stroke Screening Study (RSSS) was supported by Health and Family Planning Commission of Hebei Province (China) (12276104D-90). This study was partially supported by the Nova Program of Beijing Science and Technology Commission (2008B30), National Natural Science Foundation of China (81471208, 81641162) and Beijing high-level healthy human resource project (014-3-033).

History

Usage metrics

    Neurological Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC